Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The phase 2 obesity trial for retatrutide enrolled a separate subgroup of people with obesity and NAFLD
About 1 in 8 US adults aged 18 years or older (12% of US adults!) report having used a glucagon-like peptide 1 (GLP-1) agonist medication , according to results from a KFF (formerly Kaiser Family Foundation) poll often for weight loss rather than for diabetes
In one case, we were recommended GLP-1s even though the user was underweight (57 and 110 pounds)
This is evident in patients who had significant weight loss after bariatric surgery
Developed as part of a new class of multi-receptor agonists, Retatrutide is designed to target several hormonal pathways involved in appetite regulation, glucose metabolism, and energy expenditure
Our experienced medical team evaluates each client individually to determine the safest and most appropriate options available today
US$ 21.00
US$ 20.33
US$ 24.65
US$ 24.73
US$ 22.43
